Skip to main content

Table 2 Crude and adjusted odds ratios (ORs) with 95 % confidence intervals (CI) for the associations between characteristics of all general practices and initiating long-term treatment with PPIs

From: General practice variation when initiating long-term prescribing of proton pump inhibitors: a nationwide cohort study

  Crude OR (95 % CI) P-value Adjusted OR* (95 % CI) P-value
Patients per GP
 <1350 1 . 1 .
 1350-1575 1.03 (0.96;1.10) 0.43 1.00 (0.93;1.07) 0.90
 1576-1750 1.00 (0.94;1.08) 0.92 1.01 (0.94;1.09) 0.74
 >1750 1.01 (0.94;1.08) 0.83 1.00 (0.93;1.07) 0.94
Geography
 Capital area 1 . 1 .
 Provincial city 1.01 (0.95;1.07) 0.73 1.02 (0.96;1.09) 0.52
 Rural area 1.11 (1.04;1.19) <0.001 1.04 (0.97;1.11) 0.23
GP gender
 Male 1 . 1 .
 Predominantly male 0.81 (0.75;0.87) <0.001 0.88 (0.78;1.01) 0.07
 Equally mixed 0.77 (0.72;0.82) <0.001 0.83 (0.76;0.91) <0.001
 Predominantly female 0.76 (0.70;0.83) <0.001 0.87 (0.76;1.00) 0.04
 Female 0.77 (0.71;0.82) <0.001 0.87 (0.81;0.93) <0.001
GP age group
 Under 45 years 1 . 1 .
 45-49 years 1.02 (0.91;1.13) 0.79 0.99 (0.88;1.11) 0.86
 50-54 years 1.06 (0.95;1.17) 0.29 1.01 (0.91;1.12) 0.89
 55-59 years 1.21 (1.09;1.34) <0.001 1.12 (1.00;1.24) 0.04
 60-64 years 1.44 (1.29;1.61) <0.001 1.30 (1.16;1.46) <0.001
 65 years or above 1.46 (1.29;1.65) <0.001 1.32 (1.16;1.50) <0.001
Number of GPs
 1 1 . 1 .
 2 0.86 (0.81;0.92) <0.001 1.04 (0.95;1.13) 0.40
 3 0.83 (0.78;0.89) <0.001 1.00 (0.88;1.14) 0.99
 4 0.83 (0.76;0.91) <0.001 1.05 (0.92;1.19) 0.50
 5 0.85 (0.75;0.96) 0.01 1.01 (0.84;1.20) 0.94
 >5 0.84 (0.72;0.98) 0.03 1.01 (0.83;1.22) 0.94
Training practice
 No 1 . 1 .
 Yes 0.98 (0.93;1.03) 0.36 1.04 (0.98;1.09) 0.20
  1. *Estimates adjusted for all other practice characteristics and patient characteristics in terms of age, gender, specific gastrointestinal morbidity, socioeconomic status (income, educational level, cohabitation status), comedication with non-steroidal anti-inflammatory drugs (NSAIDs), antiplatelet drugs, anticoagulants, selective serotonine reuptake inhibitors (SSRIs) and comorbidity
\